Recent advances have seen the successful application of monoclonal antibodies and kinase inhibitors directed against VEGFA and its receptors (VEGFR1/2/3) in combating non-small cell lung cancer (NSCLC), HCC, and other malignancies [8,9,24]. Here, VEGFA is linked to hepatocellular carcinoma.